Figure 3.

Antitumor efficacy of the combination therapy with OV-OX40L/IL12 and TILs in the first PDX tumor model (OC1 PDX model)

(A) Schematic diagram of the PDX model treated with OV-OX40L/IL12 and TILs expanded from the same patient numbered OC1. NSG mice were subcutaneously implanted with patient-derived tumor tissues, and the established tumors were intratumorally injected with the indicated OV followed by intratumoral injection of ex vivo expanded TILs from the same patient. Tumor growth was measured every other day (n = 4). The average tumor volumes (B) are shown. Arrows indicate the OV, TIL, and IL2 injections. (C) Intratumor IFN-γ levels were determined by using an ELISA assay. (D) Representative images of IHC staining for HLA-A/B/C, HLA-DR, CD86, CD134, CD137, and IFN-γ in tumor tissue sections at 14 days after treatment (n = 4). Scale bars, 100 μm. The statistical analysis was determined by one-way ANOVA, followed by Tukey’s multiple comparison test analysis. All values are presented as the mean ± SEM. ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.